Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
Harbour BioMed brings advanced antibody discovery platforms to the table
Subscribe To Our Newsletter & Stay Updated
